Physician profile

John A Banzer

Cardiovascular Disease · Silverdale, WA

NPI 1912933375

$10,331.55

in general payments reported to CMS, 2019-2025

47 companies · $1,366 in 2025

The $1,366 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,126.13
Education$19.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $1,513.65 2019-2025 Jardiance, Glyxambi, Tradjenta
Amgen INC. $1,275.87 2019-2025 Repatha, Repatha, Otezla
E.R. Squibb & Sons, L.L.C. $874.22 2019-2025 Camzyos, Eliquis
Astrazeneca Pharmaceuticals LP $829.61 2019-2025 Farxiga, Brilinta, Lokelma
Novo Nordisk INC $800.64 2019-2025 Wegovy, Ozempic, Rybelsus
Novartis Pharmaceuticals Corporation $771.79 2019-2025
Bayer Healthcare Pharmaceuticals INC. $742.39 2021-2025
Pfizer INC. $597.76 2019-2025
Boston Scientific Corporation $312.58 2019-2024 Bodyguardian, Watchman Access System
Amarin Pharma, INC. $248.67 2019-2021
Alnylam Pharmaceuticals INC. $241.42 2023-2025 Amvuttra, Onpattro
Janssen Pharmaceuticals, INC $238.50 2019-2024 Xarelto
Merck Sharp & Dohme LLC $237.98 2023-2024 Verquvo
Xeris Pharmaceuticals, INC. $167.85 2021-2023 Gvoke Hypopen
Kiniksa Pharmaceuticals International, Plc $141.84 2024 Arcalyst
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Lexicon Pharmaceuticals, INC. $137.20 2023-2024 Inpefa
Otsuka America Pharmaceutical, INC. $121.31 2019-2020
Esperion Therapeutics, INC. $98.32 2020-2022
Kiniksa Pharmaceuticals, LTD. $97.59 2023 Arcalyst
Lilly USA, LLC $88.47 2019-2025 Mounjaro, Zepbound
Atricure, INC. $65.77 2023
Sanofi-Aventis U.S. LLC $64.70 2019-2021
Genzyme Corporation $46.57 2025
Chiesi USA, INC. $45.98 2023-2024 Kengreal, Cleviprex
Kyowa Kirin, INC. $44.71 2020-2023 Crysvita
Lifescan, INC. $40.49 2020-2023
Kowa Pharmaceuticals America, INC. $38.36 2019-2021
Scpharmaceuticals INC. $35.02 2025
Medtronic Vascular, INC. $30.66 2019
Insulet Corporation $30.16 2019
Lundbeck LLC $29.19 2019
Celgene Corporation $28.96 2025 Zeposia
Abiomed $28.13 2025
Abbott Laboratories $24.37 2025 Freestyle Libre 3
Bridgebio Pharma, INC. $23.64 2025 Attruby
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $22.68 2023 Lifevest
Inspire Medical Systems, INC. $22.04 2025 Inspire
Azurity Pharmaceuticals, INC. $21.88 2024 Edarbyclor
Impulse Dynamics (USA) INC. $20.95 2022
Edwards Lifesciences Corporation $20.30 2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Irhythm Technologies, INC. $19.06 2024 Zio Xt Patch, Zio Monitor
Alexion Pharmaceuticals, INC. $19.00 2024 Ultomiris
Baxter Healthcare $17.45 2024 Hillrom - Cardiac Ambulatory Monitor
Regeneron Healthcare Solutions, INC. $15.64 2019
Tanabe Pharma America, INC. $14.10 2019
Arbor Pharmaceuticals, INC. $13.13 2019
Echosens North America, INC. $10.95 2023 Fibroscan

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John A Banzer

$10,331.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $1,366 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/86236/john-a-banzer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.